Eli Lilly and Company (NYSE:LLY) Shares Purchased by Commerce Bank

by · The Markets Daily

Commerce Bank boosted its holdings in shares of Eli Lilly and Company (NYSE:LLY – Free Report) by 7.4% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 176,376 shares of the company’s stock after buying an additional 12,162 shares during the period. Eli Lilly and Company makes up 0.9% of Commerce Bank’s holdings, making the stock its 18th largest position. Commerce Bank’s holdings in Eli Lilly and Company were worth $145,671,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. MONECO Advisors LLC raised its holdings in shares of Eli Lilly and Company by 0.6% in the first quarter. MONECO Advisors LLC now owns 4,123 shares of the company’s stock worth $3,405,000 after buying an additional 23 shares during the last quarter. Moors & Cabot Inc. grew its holdings in shares of Eli Lilly and Company by 7.8% during the first quarter. Moors & Cabot Inc. now owns 22,036 shares of the company’s stock valued at $18,199,000 after buying an additional 1,598 shares during the last quarter. Nicolet Advisory Services LLC increased its position in shares of Eli Lilly and Company by 16.0% in the 1st quarter. Nicolet Advisory Services LLC now owns 3,814 shares of the company’s stock valued at $3,150,000 after acquiring an additional 527 shares during the period. Momentous Wealth Management Inc. purchased a new position in Eli Lilly and Company in the 1st quarter worth $225,000. Finally, Empirical Financial Services LLC d.b.a. Empirical Wealth Management raised its stake in Eli Lilly and Company by 74.7% in the 1st quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management now owns 12,860 shares of the company’s stock worth $10,621,000 after acquiring an additional 5,497 shares during the last quarter. 82.53% of the stock is currently owned by hedge funds and other institutional investors.

Eli Lilly and Company Price Performance

Shares of Eli Lilly and Company stock opened at $739.62 on Friday. The firm has a market cap of $700.97 billion, a PE ratio of 60.18, a P/E/G ratio of 1.08 and a beta of 0.40. Eli Lilly and Company has a twelve month low of $677.09 and a twelve month high of $972.53. The company has a quick ratio of 1.06, a current ratio of 1.37 and a debt-to-equity ratio of 2.18. The business has a 50-day moving average price of $774.56 and a 200 day moving average price of $799.73.

Eli Lilly and Company (NYSE:LLY – Get Free Report) last posted its quarterly earnings data on Thursday, May 1st. The company reported $3.34 EPS for the quarter, missing analysts’ consensus estimates of $4.64 by ($1.30). The business had revenue of $12.73 billion during the quarter, compared to analysts’ expectations of $12.77 billion. Eli Lilly and Company had a net margin of 22.67% and a return on equity of 85.51%. The firm’s quarterly revenue was up 45.2% compared to the same quarter last year. During the same quarter last year, the firm earned $2.58 earnings per share. Sell-side analysts predict that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Wednesday, September 10th. Investors of record on Friday, August 15th will be issued a $1.50 dividend. This represents a $6.00 annualized dividend and a yield of 0.8%. The ex-dividend date of this dividend is Friday, August 15th. Eli Lilly and Company’s payout ratio is presently 48.82%.

Analyst Upgrades and Downgrades

A number of brokerages have recently weighed in on LLY. Wall Street Zen raised Eli Lilly and Company from a “hold” rating to a “buy” rating in a report on Saturday, July 26th. Guggenheim increased their price target on shares of Eli Lilly and Company from $936.00 to $942.00 and gave the stock a “buy” rating in a report on Friday, July 11th. Cantor Fitzgerald initiated coverage on shares of Eli Lilly and Company in a research report on Tuesday, April 22nd. They set an “overweight” rating and a $975.00 price target for the company. HSBC cut shares of Eli Lilly and Company from a “buy” rating to a “reduce” rating and decreased their price objective for the company from $1,150.00 to $700.00 in a research note on Monday, April 28th. Finally, Erste Group Bank lowered shares of Eli Lilly and Company from a “buy” rating to a “hold” rating in a research note on Thursday, June 5th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and seventeen have issued a buy rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $1,012.56.

Check Out Our Latest Report on LLY

Eli Lilly and Company Company Profile

(Free Report)

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

Further Reading